DrugPatentWatch Database Preview

Hq Spclt Pharma Company Profile

« Back to Dashboard

What is the competitive landscape for HQ SPCLT PHARMA, and what generic alternatives to HQ SPCLT PHARMA drugs are available?

HQ SPCLT PHARMA has ten approved drugs.

There are eight US patents protecting HQ SPCLT PHARMA drugs.

There are forty-seven patent family members on HQ SPCLT PHARMA drugs in twenty-five countries and eighty-one supplementary protection certificates in fourteen countries.

Summary for Hq Spclt Pharma

International Patents:	47
US Patents:	8
Tradenames:	13
Ingredients:	9
NDAs:	10

Drugs and US Patents for Hq Spclt Pharma

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hq Spclt Pharma	CALCIUM GLUCONATE IN SODIUM CHLORIDE	calcium gluconate	SOLUTION;INTRAVENOUS	210906-002	Oct 29, 2018		RX	Yes	Yes	10,342,813		Y
Hq Spclt Pharma	LINEZOLID	linezolid	SOLUTION;INTRAVENOUS	207001-002	Jul 7, 2017	AP	RX	No	No
Hq Spclt Pharma	MEROPENEM	meropenem	INJECTABLE;INJECTION	210773-002	Aug 16, 2019	AP	RX	No	No
Hq Spclt Pharma	ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER	esmolol hydrochloride	SOLUTION;INTRAVENOUS	205703-002	Apr 7, 2016		RX	Yes	Yes	6,528,540		Y
Hq Spclt Pharma	MEROPENEM	meropenem	INJECTABLE;INJECTION	210773-001	Aug 16, 2019	AP	RX	No	No
Hq Spclt Pharma	MAGNESIUM SULFATE IN PLASTIC CONTAINER	magnesium sulfate	INJECTABLE;INJECTION	207350-005	Dec 6, 2017	AP	RX	No	No

Expired US Patents for Hq Spclt Pharma

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Hq Spclt Pharma	TAXOL	paclitaxel	INJECTABLE;INJECTION	020262-001	Dec 29, 1992	5,641,803
Hq Spclt Pharma	PLATINOL-AQ	cisplatin	INJECTABLE;INJECTION	018057-003	Jul 18, 1984	5,562,925
Hq Spclt Pharma	CISPLATIN	cisplatin	INJECTABLE;INJECTION	018057-004	Nov 8, 1988	4,177,263
Hq Spclt Pharma	TAXOL	paclitaxel	INJECTABLE;INJECTION	020262-001	Dec 29, 1992	6,150,398
Hq Spclt Pharma	PLATINOL	cisplatin	INJECTABLE;INJECTION	018057-002	Approved Prior to Jan 1, 1982	5,562,925
Hq Spclt Pharma	PLATINOL	cisplatin	INJECTABLE;INJECTION	018057-001	Approved Prior to Jan 1, 1982	5,562,925

International Patents for Hq Spclt Pharma Drugs

Country	Patent Number	Estimated Expiration
Slovenia	1368019
European Patent Office	3429574
European Patent Office	2948379
Denmark	1368019
Japan	5778384
Poland	357387

Supplementary Protection Certificates for Hq Spclt Pharma Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0720599	300689	Netherlands		PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ATORVASTATINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ATORVASTATINE CALCIUM TRIHYDRATE; NATIONAL REGISTRATION NO/DATE: RVG114373-114376 20141027; FIRST REGISTRATION: FR 2014091200122 20140912
2957286	2018/046	Ireland		PRODUCT NAME: PATIROMER SORBITEX CALCIUM; REGISTRATION NO/DATE: EU/1/17/1179 20170719
1499331	13C0055	France		PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: 434323 20130220
0984957	300483	Netherlands		PRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMTRIHYDRAAT; NATIONAL REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: GB PL 17091/0263 - 0001 20101105
0984957	122012000051	Germany		PRODUCT NAME: KOMBINATIONSPRODUKT UMFASSEND NAPROXEN UND ESOMEPRAZOL-MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105
1020461	300482	Netherlands		PRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMZOUT; NATIONAL REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: GB PL 17091/0263 - 0001 20101105

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Hq Spclt Pharma
• Hq Speciality Pharma
• Hq Speclt Pharma